Burnaby’s Kardium has enrolled the first patient in its Globe Registry, a study tracking its heart-treatment technology in routine clinical practice.
The registry is expected to include up to 500 patients across Canada and the United States, with follow-up lasting 12 months after treatment.
Researchers will assess the Globe Pulsed Field System’s safety and effectiveness in patients with atrial fibrillation. Overlake Medical Center in Bellevue, Washington, enrolled the first participant.
The milestone follows U.S. approval in 2025 and Canadian approval this summer. As commercial adoption expands, the registry will gather evidence about outcomes beyond the controlled conditions of clinical trials.
Want to know more? Check out the source code on Techcouver.com.











